RHYTHM PHARMACEUTICALS, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $80.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2025-05-07
- RHYTHM PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2025-03-31 was $80.00K, a 73.33% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2024-09-30 was $344.00K, a 6.52% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2024-06-30 was $479.00K.
- RHYTHM PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for the quarter ending 2024-03-31 was $300.00K.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 3 month | Foreign Income Tax Expense (Benefit), Continuing Operations 6 month | Foreign Income Tax Expense (Benefit), Continuing Operations 9 month |
|---|---|---|---|
| 2025-03-31 | $80.00K 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | $344.00K 10-Q · filed 2024-11-06 | $823.00K derived: sum of 2 quarters · filed 2024-11-06 | $436.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $479.00K 10-Q · filed 2024-08-06 | $779.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $368.00K 10-Q · filed 2024-11-06 | $368.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |